BWAY vs. XAIR, DCTH, TMCI, CERS, ANIK, SGHT, NVRO, OSUR, TCMD, and LUNG
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Beyond Air (XAIR), Delcath Systems (DCTH), Treace Medical Concepts (TMCI), Cerus (CERS), Anika Therapeutics (ANIK), Sight Sciences (SGHT), Nevro (NVRO), OraSure Technologies (OSUR), Tactile Systems Technology (TCMD), and Pulmonx (LUNG). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay (NASDAQ:BWAY) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
BrainsWay currently has a consensus target price of $13.00, suggesting a potential upside of 63.52%. Beyond Air has a consensus target price of $5.75, suggesting a potential upside of 805.37%. Given Beyond Air's higher possible upside, analysts plainly believe Beyond Air is more favorable than BrainsWay.
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 31.5% of Beyond Air shares are held by institutional investors. 19.0% of BrainsWay shares are held by insiders. Comparatively, 19.0% of Beyond Air shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
BrainsWay has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
In the previous week, BrainsWay had 1 more articles in the media than Beyond Air. MarketBeat recorded 4 mentions for BrainsWay and 3 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.97 beat BrainsWay's score of 0.61 indicating that Beyond Air is being referred to more favorably in the news media.
BrainsWay has a net margin of -4.83% compared to Beyond Air's net margin of -5,197.76%. BrainsWay's return on equity of -3.98% beat Beyond Air's return on equity.
BrainsWay has higher revenue and earnings than Beyond Air. BrainsWay is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
BrainsWay received 18 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.18% of users gave Beyond Air an outperform vote while only 64.95% of users gave BrainsWay an outperform vote.
Summary
BrainsWay beats Beyond Air on 9 of the 15 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
